BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors

Palo Alto, CA and Shanghai and Princeton, NJ – August 25, 2021 – LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced the first patient has been treated in a Phase 2a clinical trial of infigratinib in patients with locally […]

BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors

PALO ALTO, CA – August 18, 2021 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that it has added three new independent directors to its board: Fred Hassan, a pharmaceutical and financial […]

BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update

–Received U.S. Food and Drug Administration (FDA) approval for TRUSELTIQ™ (infigratinib) under the accelerated approval program for patients with cholangiocarcinoma (CCA) –Received FDA Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia (ADH1) –Received FDA Fast Track designation for investigational gene therapy designed for the treatment of congenital adrenal hyperplasia (CAH) –Ended […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Palo Alto, CA, August 4, 2021 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that on August 3, 2021, the compensation committee of BridgeBio’s board of directors granted 17 new employees […]